By Joshua D. Wright, Wall Street Journal
The Federal Trade Commission finished hearing testimony last week in its administrative proceeding aimed at forcing a genomics-sequencing company, Illumina , to reverse its recent acquisition of a startup whose blood test can detect many early-stage cancers.
Ordinarily, this is an acquisition the FTC would approve. The decision to challenge Illumina indicates a radically different approach to antitrust that will prove suffocating.
